Sagent Pharmaceuticals Launches Paclitaxel Injection, USP

Sagent Pharmaceuticals, Inc.

today announced the launch of Paclitaxel Injection, USP, a chemotherapy drug, in 30 mg, 100 mg and 300 mg latex-free, multi-dose vials. According to IMS, the 2011 U.S. market for generic injectable paclitaxel approximates $46 million. As with all products in Sagent's portfolio, paclitaxel features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. "Paclitaxel is currently on the American Society of Health-System Pharmacists' and the U.S. FDA drug shortage lists and we are pleased to be able to help supply this vital chemotherapy option to patients," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The launch of paclitaxel expands our rapidly growing portfolio of injectable oncolytics to six products."